Michele Iori

Graduated in 2004 in Chemical Sciences and Technologies from the University of Parma. In 2007, he obtained a Master's Degree in Inorganic Chemistry with a thesis titled "Metallated zwitterionic Pd (II) with the ligand EtNHC (S) PPh2NPPh2C (S) NEt." At the same university, in 2012, he completed the post-graduation in Clinical Biochemistry with a thesis on "Synthesis and use of [18F]-Fluoroethylcholine for diagnosis in nuclear medicine." After completing the master's degree, he worked in the laboratories of the Faculty of Chemistry on a project for the development of analytical methods and AT-IR spectroscopy combined with multivariate analysis for the determination of metallic chelates.

In late 2007, he was hired by the Nuclear Medicine Unit of AUSL-IRCCS as a Radiochemist, focusing on the development and optimization of synthesis methods for PET and experimental radiopharmaceuticals. Since 2010, he has been the Production Manager at the Radiopharmaceutical Chemistry Laboratory (RACHEL), conducting research on the radiolabeling of new molecules, synthesis methods, and quality control methods. More recently, following the accreditation of the Nuclear Medicine Facility for participation in Phase 1 Studies, he has been involved in the radiochemical aspects of these studies ensuring laboratory compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards.